Member Info for lukedrywaller

https://twitter.com/Tweet_trader01/status/1285300323700166656?s=19

https://twitter.com/Tweet_trader01/status/1284891499369500673?s=19

https://twitter.com/Tweet_trader01/status/1284104279138213890?s=20

https://twitter.com/Tweet_trader01/status/1281875216797491200?s=19

https://twitter.com/AntMwah/status/1279829368722853893?s=19

https://twitter.com/QuickTake/status/1277688140958961672?s=19

That made me laugh out loud

nearly 17k followers so puts the word out if anything

https://twitter.com/Justsharesonaim/status/1275059113907519489?s=20

#AVCT Looks to be moving up very nicely indeed. It’s created a small harmonic that will help along the way (yellow) that will target 168p then upper target will become into play 227p pretty much nailed this one

Worth another watch

https://**********.brand.live/c/avacta-Investor-presentation

https://twitter.com/Tweet_trader01/status/1273324417905561603?s=19

https://twitter.com/EricTopol/status/1273306544440934403?s=19

Alan green very bullish!!

https://twitter.com/Tweet_trader01/status/1273262756045762560?s=20

Partnerships with distributors and OEM partners
I expect any day

https://twitter.com/Tweet_trader01/status/1272110227173904384?s=20

Banjo?

https://twitter.com/IndependentSage/status/1269888287847714817?s=19

Rapid antigen testing is the only way out of this

The re-rate starts tomorrow

, I am delighted to report that the placing has received overwhelming support from both institutional and retail investors leading to a bookbuild that was multiple times oversubscribed. I would like to thank our existing investors and welcome new shareholders to Avacta. We are very pleased to have added a significant strategic US investor to our register.

This substantial fundraising allows us to rapidly expand the in-house Affimer® and pre|CISION™ cancer therapy pipelines and scale-up the diagnostics business to expand the Affimer® diagnostic products pipeline. In the short term the funds will provide the Company with the working capital to support the development and manufacture of the COVID-19 antigen tests in development which, given the potential demand, could be transformational for Avacta.



The Board anticipates strong near-term news flow relating to the COVID-19 test developments with Cytiva and Adeptrix, as well as commercial and technical progress in the established therapeutic and diagnostics businesses, allowing the Company to concurrently achieve multiple value inflection points that we expect will deliver substantial shareholder returns. I look forward to updating the market on our continued progress."

https://twitter.com/Tweet_trader01/status/1269230608603111427?s=09

https://twitter.com/Tweet_trader01/status/1268610765583380481?s=09